Half-year report · HY
3151.TEDINET S100X430
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥300.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥600.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥297.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥1.6bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥2.9bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥5.0bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥7.0bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.6bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥7.5bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.7bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.0bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥7.3bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.4bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥5.0bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥2.5bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥313.6bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥299.4bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥317.6bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥203.9bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥192.1bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥109.8bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥107.3bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥109.6bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥23.8bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥23.1bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥20.2bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥20.2bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥20.1bn | at 2025-03-31 | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥16.1bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥31.1bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥4.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥8.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥9.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥2.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥3.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥2.1bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥6.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥102.84 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥149.02 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥48.75 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 34.5% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.4% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.1% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 47
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥6.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥6.9bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | ¥31m |
| Medical Products Wholesalereportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥287.4bn |
| Medical Products Wholesalereportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥282.0bn |
| Medical Products Wholesalereportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥5.5bn |
| Medical Products Wholesalereportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥2.1bn |
| Nursing Care Related Rental And Other Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥3.6bn |
| Nursing Care Related Rental And Other Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥2.2bn |
| Nursing Care Related Rental And Other Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥1.4bn |
| Nursing Care Related Rental And Other Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥122m |
| Pharmaceutical Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥592m |
| Pharmacy Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥9.9bn |
| Pharmacy Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥9.9bn |
| Pharmacy Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥6m |
| Pharmacy Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥135m |
| Veterinary Drugs Wholesale Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥6.2bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥6.2bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥0 |
| Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥108m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥307.1bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥300.2bn |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥6.9bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥1.6bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥6.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥6.8bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | ¥0 |
| Medical Products Wholesalereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥285.0bn |
| Medical Products Wholesalereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥279.5bn |
| Medical Products Wholesalereportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥5.5bn |
| Medical Products Wholesalereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥2.7bn |
| Nursing Care Related Rental And Other Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.5bn |
| Nursing Care Related Rental And Other Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.2bn |
| Nursing Care Related Rental And Other Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1.3bn |
| Nursing Care Related Rental And Other Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥88m |
| Pharmacy Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥9.7bn |
| Pharmacy Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥9.7bn |
| Pharmacy Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6m |
| Pharmacy Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥96m |
| Veterinary Drugs Wholesale Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.6bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.6bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥144m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥303.9bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥297.1bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6.8bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥2.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 539
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任監査法人トーマツ | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)菊 池 寛 康 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)福 士 直 和 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1InterimDuration | 297079000000 | JPY |
| Net sales (5-year summary) | InterimDuration | 300234000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 600370000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1InterimDuration | 3637000000 | JPY |
| Ordinary income loss (5-year summary) | InterimDuration | 5042000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 6970000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1InterimDuration | 2420000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | InterimDuration | 4968000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 7308000000 | JPY |
| Comprehensive income (5-year summary) | Prior1InterimDuration | 6361000000 | JPY |
| Comprehensive income (5-year summary) | InterimDuration | 3485000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 5931000000 | JPY |
| Net assets (5-year summary) | Prior1InterimInstant | 109626000000 | JPY |
| Net assets (5-year summary) | InterimInstant | 109750000000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 107306000000 | JPY |
| Total assets (5-year summary) | Prior1InterimInstant | 317568000000 | JPY |
| Total assets (5-year summary) | InterimInstant | 313615000000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 299426000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1InterimDuration | 48.75 | |
| Basic earnings loss per share (5-year summary) | InterimDuration | 102.84 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 149.02 | |
| Diluted earnings per share (5-year summary) | Prior1InterimDuration | － | |
| Diluted earnings per share (5-year summary) | InterimDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior1InterimInstant | 0.341 | |
| Equity to asset ratio (5-year summary) | InterimInstant | 0.345 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.354 | |
| Net cash provided by used in operating activities (5-year summary) | Prior1InterimDuration | -9673000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | InterimDuration | 4319000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | -8024000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1InterimDuration | -1634000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | InterimDuration | -2205000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | 3516000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1InterimDuration | -3732000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | InterimDuration | -2127000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | -6543000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1InterimInstant | 16084000000 | JPY |
| Cash and cash equivalents (5-year summary) | InterimInstant | 20200000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 20074000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 51902976 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 51902976 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 51902976 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 51902976 | |
| Number of shares held | InterimInstant_No1MajorShareholdersMember | 4892000 | |
| Shareholding ratio | InterimInstant_No1MajorShareholdersMember | 0.1009 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |